| Product Name | Goserelin |
| Synonyms | Zoladex, ICI 118630, Decapeptide I, [D-Ser(tBu)6, Azgly10]-LHRH |
| CAS Number | 65807-02-5 (free base); acetate salt 145781-92-6 |
| Sequence (3-Letter) | pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH₂ |
| Sequence (1-Letter) | pGlu-HWSY-dSer(tBu)-LRP-AzGly-NH₂ (position 6 D-Ser(tBu); position 10 azaglycine) |
| Molecular Formula | C₅₉H₈₄N₁₈O₁₄ (free base) |
| Molecular Weight | 1269.41 (free base) |
| Category | Drug Peptide – GnRH (LHRH) Agonist |
| Purity | ≥98% (by HPLC) |
| Appearance | White to off-white powder |
| Counter Ion | Acetate (free base / TFA-free available; salt form per specification) |
| Peptide Content | ≥80% (per specification) |
| Solubility | Soluble in water and dilute acetic acid |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – kg (research quantities to scale-up batches) |
| QC Documentation | COA, HPLC, MS identity (additional API/regulatory documentation on request) |
| Usage | For research and pharmaceutical development use, and as a reference standard or active pharmaceutical ingredient for manufacturing. Not for human or veterinary use; not for sale to patients. Any therapeutic use is subject to applicable regulatory approval. |
Goserelin is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) agonist, also called an LHRH agonist, known as a medicine under the brand name Zoladex (CAS 65807-02-5; acetate salt 145781-92-6). Its sequence is pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2, built from natural GnRH with a D-serine tert-butyl ether at position six and an azaglycine at position ten, which make it potent and resistant to breakdown. We supply it as a white powder for research and pharmaceutical development.
Goserelin is a GnRH agonist. Given continuously, usually from a depot implant, it first briefly stimulates the pituitary and then downregulates its GnRH receptors, so the pituitary releases much less LH and FSH. Lower LH and FSH in turn lower the body's sex hormones, testosterone in men and estrogen in women, to very low levels. Its position-six and position-ten changes give it a long, strong action.
Clinically, goserelin is used in hormone-dependent conditions, including prostate cancer, breast cancer, and endometriosis, and to thin the lining of the uterus before some procedures. This is background information only; the material we supply is for research and pharmaceutical manufacturing use, and is not for human or veterinary use and not for sale to patients.
We supply Goserelin with a certificate of analysis, HPLC purity data, and mass-spec identity confirmation. Additional documentation for API and regulatory work is available on request, and salt form and purity can be set to your specification.
Yes. We manufacture Goserelin in-house and supply from research quantities up to scale-up batches. Contact us with your required purity, salt form, and quantity for a quote.
Goserelin is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) agonist. It is known as a medicine under the brand name Zoladex, where it is given as a long-acting depot implant. We supply it as a raw material for research and pharmaceutical development.
Goserelin is a ten-residue peptide with the sequence pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2. It is built on the natural GnRH backbone with two key changes: a D-serine carrying a tert-butyl ether at position six, and an azaglycine at position ten, in which the alpha-carbon of the final residue is replaced by nitrogen. Both changes make it more potent and far more resistant to enzymatic breakdown. Its free-base CAS number is 65807-02-5 (acetate salt 145781-92-6), its molecular formula is C59H84N18O14, and its molecular weight is about 1269.
Goserelin is an agonist at the GnRH receptor. When it is given continuously, typically from a slow-release depot, it first causes a short burst of pituitary stimulation, then the GnRH receptors downregulate and the pituitary releases much less luteinising hormone (LH) and follicle-stimulating hormone (FSH). Because LH and FSH drive the gonads, their suppression lowers sex-hormone production, reducing testosterone in men and estrogen in women. This is the same overall behaviour as other GnRH agonists such as triptorelin.
Goserelin is used clinically in hormone-dependent conditions, including prostate cancer, breast cancer, and endometriosis, and to thin the lining of the uterus before some procedures. This information is provided as scientific and reference background only. The material supplied by SynPeptide is intended for research and pharmaceutical manufacturing, is not for human or veterinary use, and is not for sale to patients; any therapeutic use is subject to applicable regulatory approval.
We supply Goserelin with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, with further documentation available to support active pharmaceutical ingredient and regulatory work. Purity, salt form, and counter-ion can be set to your specification for use as a reference standard or in process development.
We manufacture Goserelin by solid-phase synthesis, including the D-serine tert-butyl ether and the azaglycine residue, and supply it from research quantities through to scale-up batches. For related capabilities, see drug peptides, custom peptide synthesis, and peptide modification. Material is supplied for research and pharmaceutical manufacturing use only.
